GlassScriptPhysician profile
Hema Korlakunta
NPI 1174604789
$3,862.87
in general payments reported to CMS, 2019-2025
9 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.98 · 2020: $85.91 · 2021: $152 · 2022: $2,058 · 2023: $1,261 · 2024: $160 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,051 · Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,051.05 |
| Food and Beverage | $481.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,043.67 | 2022 | |
| Abiomed | $1,325.84 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.53 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.65 | 2024 | Jardiance |
| Abbott Laboratories | $56.58 | 2019-2021 | |
| Philips North America LLC | $35.35 | 2020 | |
| Chiesi USA, INC. | $18.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hema Korlakunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.